BIOPHARMA
ByThe Best Feeling Is When Our Drugs Succeed”: Dame Emma Walmsley Reflects on GSK’s Legacy of Innovation
London | December 2025 GlaxoSmithKline (GSK) today highlighted a defining reflection from its outgoing Chief Executive Officer, Dame…
Neuroscience Biopharma in Transformation: Pipeline and Commercial Dynamics Reshape the Industry
Washington, D.C. — The neuroscience segment is undergoing a significant strategic transformation, driven by breakthroughs in neurodegenerative, psychiatric,…
How Will New U.S. Drug Pricing Policies Reshape the Pharmaceutical Ecosystem?
Washington, D.C. — December 29, 2025 — Recent changes in U.S. drug pricing policies are fundamentally reshaping the…
How Did Merck’s 2025 Deals Strengthen Its Pipeline and What Could They Mean for Future Growth?
In 2025, Merck pursued a series of high-impact collaborations, acquisitions, and licensing agreements to expand its portfolio, enhance…
Can Amgen’s 2025 Approvals and Launches Strengthen Its Oncology, Cardiovascular, and Bone Health Leadership Into 2026?
Global | January 2026 — Amgen Inc. achieved key milestones in 2025, marked by multiple regulatory approvals, label…
Can GSK’s 2025 Approvals and Launches Strengthen Its Vaccines, Respiratory, and Immunology Leadership Into 2026?
Global | January 2026 — GlaxoSmithKline PLC (GSK) achieved key milestones in 2025, with multiple regulatory approvals, product…
